GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Quick Ratio

Knight Therapeutics (TSX:GUD) Quick Ratio

: 2.40 (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Knight Therapeutics's quick ratio for the quarter that ended in Dec. 2023 was 2.40.

Knight Therapeutics has a quick ratio of 2.40. It generally indicates good short-term financial strength.

The historical rank and industry rank for Knight Therapeutics's Quick Ratio or its related term are showing as below:

TSX:GUD' s Quick Ratio Range Over the Past 10 Years
Min: 1.79   Med: 23.03   Max: 81.88
Current: 2.4

During the past 11 years, Knight Therapeutics's highest Quick Ratio was 81.88. The lowest was 1.79. And the median was 23.03.

TSX:GUD's Quick Ratio is ranked better than
71.88% of 1074 companies
in the Drug Manufacturers industry
Industry Median: 1.325 vs TSX:GUD: 2.40

Knight Therapeutics Quick Ratio Historical Data

The historical data trend for Knight Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 4.37 2.23 2.14 2.40

Knight Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.14 2.25 2.36 2.51 2.40

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics Quick Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Quick Ratio falls into.



Knight Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Knight Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(365.115-91.834)/114.029
=2.40

Knight Therapeutics's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(365.115-91.834)/114.029
=2.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Knight Therapeutics  (TSX:GUD) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Knight Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Knight Therapeutics (TSX:GUD) Business Description

Traded in Other Exchanges
Address
3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Executives
Sime Armoyan 10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines